Friday Dec 5, 2025
NEWSLETTER
www.israelhayom.com
  • Home
  • News
    • Israel
    • Israel at War
    • Middle East
    • United States
  • Opinions
  • Jewish World
    • Archaeology
    • Antisemitism
  • Lifestyle
    • Food
    • Travel
    • Fashion
    • Culture
  • Magazine
    • Feature
    • Analysis
    • Explainer
  • In Memoriam
www.israelhayom.com
  • Home
  • News
    • Israel
    • Israel at War
    • Middle East
    • United States
  • Opinions
  • Jewish World
    • Archaeology
    • Antisemitism
  • Lifestyle
    • Food
    • Travel
    • Fashion
    • Culture
  • Magazine
    • Feature
    • Analysis
    • Explainer
  • In Memoriam
www.israelhayom.com
Home Economy

Teva settles with Oklahoma for $85 million in opioid case

Funds to be used to fight the opioid crisis in Oklahoma, says state Attorney General Mike Hunter. Under terms of agreement, Teva does not admit any wrongdoing.

by  Associated Press and Israel Hayom Staff
Published on  05-27-2019 12:18
Last modified: 09-23-2019 13:32
Teva settles with Oklahoma for $85 million in opioid caseReuters/Baz Ratner

FILE PHOTO: A building belonging to generic drug producer Teva is seen in Jerusalem March 23, 2010. | Photo: Reuters/Baz Ratner

Share on FacebookShare on Twitter

One of the drugmakers named in Oklahoma's lawsuit over the opioid crisis has agreed to a settlement in which it will pay the state $85 million.

Israeli-owned Teva Pharmaceuticals and Oklahoma Attorney General Mike Hunter both announced the settlement on Sunday in separate statements. Teva, its related affiliates, Johnson & Johnson and several of its subsidiaries were set to go to trial Tuesday in Norman, Oklahoma.

Hunter said the case against Johnson & Johnson will proceed on schedule.

He also said that the funds from the settlement with Teva will be used to fight the opioid crisis in Oklahoma.

Teva did not admit any wrongdoing under the settlement.

Earlier this year, Oklahoma settled with OxyContin-maker Purdue Pharma for $270 million.

Tags: Oklahomaopioid crisisopioidspharmaTevaTeva Pharmaceuticals

Related Posts

Investing guru explains Wall Street's 'greatest show on earth'Getty Images / urfinguss

$400 million liquidation sparks new crypto collapse in Bitcoin, Ethereum

by Erez Linn

Shares tied to digital assets in Asia receded after China's central bank cautioned about illegal acts.

Google's Gemini 3 Pro arrives: Is it a game-changer?REUTERS/Dado Ruvic; Yossi Hai Hanuka Photo: AP Photo/Jeff Chiu, File

Alphabet's market cap approaches $4 trillion amid AI rally

by Erez Linn

Stock climbed nearly 70% this year, outpacing rivals. Strong cash flow, in-house chips, and successful Gemini 3 model have made...

Israel central bank announces 25 points cut; first time in two yearsGetty Images/Oren Ben Hakoon

Israel central bank announces 25 points cut; first time in two years

by Erez Linn

Bank of Israel shifts policy, cuts interest rate by a quarter point amid falling inflation.

Menu

Analysis 

Archaeology

Blogpost

Business & Finance

Culture

Exclusive

Explainer

Environment

 

Features

Health

In Brief

Jewish World

Judea and Samaria

Lifestyle

Cyber & Internet

Sports

 

Diplomacy 

Iran & The Gulf

Gaza Strip

Politics

Shopping

Terms of use

Privacy Policy

Submissions

Contact Us

About Us

The first issue of Israel Hayom appeared on July 30, 2007. Israel Hayom was founded on the belief that the Israeli public deserves better, more balanced and more accurate journalism. Journalism that speaks, not shouts. Journalism of a different kind. And free of charge.

All rights reserved to Israel Hayom

Hosted by sPD.co.il

  • Home
  • News
    • Israel at War
    • Israel
    • United States
    • Middle East
    • Sports
  • Opinions
  • Jewish World
    • Archaeology
    • Antisemitism
  • Lifestyle
    • Food
    • Travel
    • Fashion
    • Culture
  • Magazine
    • Feature
    • Analysis
    • Explainer
    • Environment & Wildlife
    • Health & Wellness
  • In Memoriam
  • Subscribe to Newsletter
  • Submit your opinion
  • Terms and conditions

All rights reserved to Israel Hayom

Hosted by sPD.co.il

Newsletter

[contact-form-7 id=”508379″ html_id=”isrh_form_Newsletter_en” title=”newsletter_subscribe”]

  • Home
  • News
    • Israel at War
    • Israel
    • United States
    • Middle East
    • Sports
  • Opinions
  • Jewish World
    • Archaeology
    • Antisemitism
  • Lifestyle
    • Food
    • Travel
    • Fashion
    • Culture
  • Magazine
    • Feature
    • Analysis
    • Explainer
    • Environment & Wildlife
    • Health & Wellness
  • In Memoriam
  • Subscribe to Newsletter
  • Submit your opinion
  • Terms and conditions

All rights reserved to Israel Hayom

Hosted by sPD.co.il